INTERVIEW: Clinuvel's Philippe Wolgen on Scenesse and the patient factor
This article was originally published in Scrip
Executive Summary
Not many pharmaceutical executives would take credit for helping to steer the European Medicines Agency in a particular direction when it comes to assessing new innovative medicines. But that's what Philippe Wolgen, CEO of the Australian rare diseases company Clinuvel, claims to have achieved when he decided to seek EU approval for the ground-breaking phototoxicity drug Scenesse with the close involvement of patients and physicians.
You may also be interested in...
Interview: Clinuvel, A Company That Does The Unusual
“There will be one price and no discounts, no backroom deals, no incentives off the record.” In an interview with the Pink Sheet, Clinuvel UK’s general manager Lachlan Hay talked about the company’s unusual pricing policy for its equally unusual photoprotective therapy, Scenesse (afamelanotide), its frustrations at out-of-sync regulatory and market access systems, and how its plans for a US regulatory filing are going.
Dutch See First European Launch Of Clinuvel's Scenesse For Phototoxicity In EPP
Clinuvel is beginning the commercial launch in Europe of its orphan drug Scenesse for patients with erythropoietic protoporphyria, a rare condition that causes severe anaphylactic reactions and burns when the skin is exposed to sunlight.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.